Ticker brief
SMMT SUMMIT THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$15.47
1 day
-0.5%
14 days
-12.1%
mkt cap
$12.0B
signals 14d
28
authors 14d
13
crowd 14d
+0.1σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 115% mid · 65 pctile own 1y | IV/HV 1.35× |
| Skew — 25Δ RR 30d | +0.024 65 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.24 elevated | 5-session Δ +0.29 (as of 2026-07-07) |
| OI alarm | quiet | last alarm 2026-06-16 (z=2.1) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-16 · now +0.70 (−1 bearish … +1 bullish)
Who spoke13
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Biotech2k1 | A | +1.11 | 8 | +0.11 |
| @BiopharmIQ | B | · | 6 | +0.12 |
| @Brad_E_Schulz | C | · | 2 | +0.35 |
| @TheNewMoney_app | C | · | 2 | +0.35 |
| @OptionsFlowBoss | C | · | 2 | +0.22 |
| @BlueJay87476298 | B | -0.85 | 1 | +0.40 |
| @CNBC | C | +0.31 | 1 | +0.40 |
| @InvestmentGuru_ | C | -2.08 | 1 | +0.40 |
| @zohmbastic | C | -2.94 | 1 | +0.30 |
| @bullishchart | C | -1.21 | 1 | +0.40 |
| @oratnek_ill | C | -0.96 | 1 | +0.20 |
| @bioinvestor24 | A | -0.87 | 1 | -0.80 |
| @BPharmCatalyst | C | · | 1 | +0.00 |
Recent signals28of 28 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @Biotech2k1 | +0.70 | Added MIRM, COGT, SMMT and IMNM this morning. — The author explicitly reports adding four biotech positions. | +5.7% | tweet ↗ |
| 2026-10-15 | @OptionsFlowBoss | +0.00 | Shares SMMT open-interest changes without a textual directional interpretation. | +0.7% | tweet ↗ |
| 2026-10-14 | @BPharmCatalyst | +0.00 | Flags three biotech companies with potentially market-moving FDA decisions due in November. | +2.2% | tweet ↗ |
| 2026-10-14 | @OptionsFlowBoss | +0.45 | Reports detected bullish call-spread activity, implying positive options positioning. | +2.2% | tweet ↗ |
| 2026-10-13 | @TheNewMoney_app | +0.35 | Reports a purchase of SMMT $27 calls. | -0.3% | tweet ↗ |
| 2026-10-13 | @TheNewMoney_app | +0.35 | Reports a purchase of SMMT $21 calls. | -0.3% | tweet ↗ |
| 2026-10-13 | @bioinvestor24 | -0.80 | Argues SMMT's PD-1/VEGF strategy will struggle against generic Keytruda and healthcare-system changes. | -0.3% | tweet ↗ |
| 2026-10-12 | @Biotech2k1 | +0.45 | Discloses small purchases and willingness to sell if valuations become excessive. | -9.7% | tweet ↗ |
| 2026-10-12 | @Biotech2k1 | -0.35 | Sell MIRM into the rally, then reduce SMMT and DFTX. — States a concrete sequence for selling MIRM and subsequently reducing SMMT and DFTX. | -9.7% | tweet ↗ |
| 2026-10-11 | @BiopharmIQ | +0.00 | Provides a Q4 watchlist of Phase 2 and Phase 3 biotech catalysts. | -12.1% | tweet ↗ |
| 2026-10-11 | @BiopharmIQ | +0.00 | Reports relative hedge-fund holder counts for three biotech catalyst names. | -12.1% | tweet ↗ |
| 2026-10-09 | @Biotech2k1 | +0.20 | Added MDGL while retaining other names as potential sources of cash. — Explicitly adds MDGL and explains a value-focused portfolio funding plan. | -12.1% | tweet ↗ |
| 2026-10-07 | @oratnek_ill | +0.20 | Daily watchlist identifies pivot, trend-break and high-volume setups; output is capped at six tickers. | -13.8% | tweet ↗ |
| 2026-10-07 | @bullishchart | +0.40 | Bullish MACD crossover scan reports SMMT above its 20-day moving average. | -13.8% | tweet ↗ |
| 2026-10-07 | @Brad_E_Schulz | +0.30 | Quantifies intraday sector breadth and performance; ticker output is capped at six movers. | -13.8% | tweet ↗ |
| 2026-10-07 | @Brad_E_Schulz | +0.40 | Lists stocks up at least 4% on elevated intraday volume; capped at six. | -13.8% | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | -0.35 | Buy LABD if meme biotech rallies enough, using SMMT gains within a long/short strategy. — Plans a conditional biotech hedge while holding realizable gains in SMMT. | -13.8% | tweet ↗ |
| 2026-10-07 | @zohmbastic | +0.30 | Says SMMT is catching momentum. | -13.8% | tweet ↗ |
| 2026-10-07 | @Biotech2k1 | +0.10 | Sell SMMT if it reaches the existing GTC sale price. — Reports an active GTC exit order that may soon be reached. | -13.8% | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | +0.00 | Lists November PDUFA catalyst dates for AGIO, SMMT and VRTX therapies. | -10.6% | tweet ↗ |
| 2026-10-05 | @InvestmentGuru_ | +0.40 | Jefferies rates SMMT Buy with a $25 target ahead of specified clinical and FDA catalysts. | -10.4% | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | +0.25 | Weekly biotech roundup highlights patent, investment, clinical-data and analyst developments. | -10.4% | tweet ↗ |
| 2026-10-05 | @CNBC | +0.40 | AstraZeneca's CEO says a Summit drug could underpin next-generation cancer combinations after a $2 billion investment. | -10.4% | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | +0.10 | Premarket biotech-mover list pairs six leading gains with their stated catalysts. | -10.4% | tweet ↗ |
| 2026-10-05 | @Biotech2k1 | -0.35 | Plans to sell SMMT if it reaches the standing GTC sale price. — Identifies SMMT as nearest to a preset sell order during a prospective rally. | -10.4% | tweet ↗ |
| 2026-10-04 | @BlueJay87476298 | +0.40 | Argues Kodiak's rally and AstraZeneca's Summit investment validate AP Biosciences' bispecific-antibody strategy. | -7.7% | tweet ↗ |
| 2026-10-03 | @BiopharmIQ | +0.35 | Lists major weekly biotech movers and the company-specific catalysts behind their moves. | -7.7% | tweet ↗ |
| 2026-10-02 | @Biotech2k1 | +0.45 | Names six biotech companies repeatedly selected for potential 20-year returns. | -7.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.